Page 275 - Demo

Reporting of genetic diagnoses in multidisciplinary intellectual disability care2738References 1. Pinchefsky E, Shevell M. Intellectual Disabilities and Global Developmental Delay. In: Handbook of DSM-5 Disorders in Children and Adolescents. 2017. 2. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. Arlington. 2013. 3. Pekeles H, Accogli A, Boudrahem-Addour N, Russell L, Parente F, Srour M. Diagnostic Yield of Intellectual Disability Gene Panels. Pediatr Neurol. 2019;92. 4. Anazi S, Maddirevula S, Faqeih E, Alsedairy H, Alzahrani F, Shamseldin HE, et al. Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield. Mol Psychiatry. 2017;22(4). 5. Maia N, Nabais Sá MJ, Melo-Pires M, de Brouwer APM, Jorge P. Intellectual disability genomics: current state, pitfalls and future challenges. Vol. 22, BMC Genomics. 2021. 6. Savatt JM, Myers SM. Genetic Testing in Neurodevelopmental Disorders. Vol. 9, Frontiers in Pediatrics. 2021. 7. Hoytema van Konijnenburg EMM, Wortmann SB, Koelewijn MJ, Tseng LA, Houben R, StöcklerIpsiroglu S, et al. Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app. Vol. 16, Orphanet Journal of Rare Diseases. 2021. 8. Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): Current perspectives. Therapeutics and Clinical Risk Management. 2019. 9. Van Eeghen AM, Bruining H, Wolf NI, Bergen AA, Houtkooper RH, Van Haelst MM, et al. Personalized medicine for rare neurogenetic disorders: can we make it happen? Cold Spring Harb Mol Case Stud. 2022;8(2):a006200. 10. Coppus AMW. People with intellectual disability: What do we know about adulthood and life expectancy? Vol. 18, Developmental Disabilities Research Reviews. 2013. 11. Both P, ten Holt L, Mous S, Patist J, Rietman A, Dieleman G, et al. Tuberous sclerosis complex: Concerns and needs of patients and parents from the transitional period to adulthood. Epilepsy Behav. 2018. 12. Van Remmerden MC, Hoogland L, Mous SE, Dierckx B, Coesmans M, Moll HA, et al. Growing up with Fragile X Syndrome: Concerns and Care Needs of Young Adult Patients and Their Parents. J Autism Dev Disord. 2020. 13. Davis AS, Phelps LA. Psychoeducational Implications of Neurodevelopmental Genetic Disorders. Sch Psychol Q. 2008;23(2). 14. Egger J, Egger C, Woodcock K, De Witte L, Van Den Bree M, Van Dongen L, et al. Editorial: Treatment of psychopathological and neurocognitive disorders in genetic syndromes: In need of multidisciplinary phenotyping and treatment design. Vol. 13, Frontiers in Psychiatry. 2022. 15. Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123. 16. VZinfo. Volksgezondheid en Zorg: Verstandelijke beperking | Leeftijd en geslacht [Internet]. [cited 2023 May 30]. Available from: https://www.vzinfo.nl/verstandelijke-beperking/leeftijden-geslacht.17. Finucane BM, Ledbetter DH, Vorstman JA. Diagnostic genetic testing for neurodevelopmental psychiatric disorders: closing the gap between recommendation and clinical implementation. Vol. 68, Current Opinion in Genetics and Development. 2021. 18. Oliver C, Adams D, Allen D, Bull L, Heald M, Moss J, et al. Causal Models of Clinically Significant Behaviors in Angelman, Cornelia de Lange, Prader-Willi and Smith-Magenis Syndromes. In: International Review of Research in Developmental Disabilities. 2013. 19. Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, et al. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs. 2016;76(5). Annelieke Muller sHL.indd 273 14-11-2023 09:08